Product image of Lanreotid Sun (Lanreotide) supplied by GNH India

Lanreotid Sun

Active Ingredient:
Lanreotide
Origin:
EU

Lanreotid Sun (Lanreotide)

Lanreotide, the active ingredient in Lanreotid Sun, is a somatostatin analog presented as a sterile solution for subcutaneous use. It is employed to control hormone excess in conditions such as acromegaly and certain neuroendocrine tumors, reducing abnormal growth hormone and peptide secretion.

GNH India supplies Lanreotid Sun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation for global distribution, ensuring product integrity and timely delivery.

Manufacturer / TM Owner

Sun Pharmaceutical Industries Europe B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lanreotide is used to manage disorders driven by excess secretion of growth hormone or peptide hormones.

  • Acromegaly: reduces elevated growth hormone levels and associated tissue overgrowth.
  • Neuroendocrine tumors (carcinoid): controls hormone‑related symptoms and may limit tumor progression.
  • Hormone‑secreting tumors: suppresses abnormal peptide hormone release, aiding symptom control.

How It Works

  • Lanreotide is a synthetic analogue of somatostatin that binds with high affinity to somatostatin receptor subtypes 2 and 5 on target cells. Receptor activation inhibits adenylate cyclase activity, decreasing cyclic AMP and calcium influx, which suppresses secretion of growth hormone, insulin, glucagon, and various gastrointestinal peptides, thereby reducing hormone‑driven disease activity. The prolonged receptor occupancy results in sustained inhibition of hormonal bursts.

Side Effects

Lanreotide may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects

  • Injection site reactions: pain, erythema, or swelling at the subcutaneous site.
  • Gastrointestinal disturbances: nausea, abdominal pain, diarrhea, or constipation.
  • Gallbladder changes: biliary sludge or gallstones.
  • Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.
  • Headache: mild to moderate head pain.
  • Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects

  • Pancreatitis: inflammation of the pancreas presenting with severe abdominal pain.
  • Severe allergic reactions: anaphylaxis, urticaria, or angioedema.
  • Cardiac arrhythmias: irregular heart rhythms reported in rare cases.

Precautions & Warnings

When prescribing Lanreotide, clinicians should consider several precautionary measures to ensure safe use.

  • Assess baseline hormone levels: evaluate growth hormone, IGF‑1, and relevant peptide concentrations before initiation.
  • Monitor glucose metabolism: check fasting glucose and HbA1c periodically, especially in patients with diabetes.
  • Evaluate gallbladder status: perform ultrasound if history of gallstones or biliary disease.
  • Review cardiac history: consider ECG monitoring in patients with known arrhythmias.
  • Adjust for renal or hepatic impairment: dose may need modification in severe organ dysfunction.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Lanreotide can interact with other medicines, affecting its efficacy or safety profile.

Major Interactions (Avoid)

  • Cyclosporine: may increase lanreotide plasma concentrations, raising risk of adverse effects.
  • Somatostatin receptor antagonists: can diminish therapeutic effect of lanreotide.

Moderate Interactions (Monitor Closely)

  • Oral hypoglycemic agents: lanreotide may alter glucose control, requiring dose adjustments.
  • Hormone replacement therapies: potential additive suppression of endogenous hormone secretion.
  • Anticoagulants: rare reports of altered bleeding risk; monitor coagulation parameters.

Frequently Asked Questions

Lanreotid Sun, containing the somatostatin analogue lanreotide, is indicated for the treatment of acromegaly, for controlling symptoms of neuroendocrine (carcinoid) tumors, and for managing other hormone‑secreting tumors that produce excess peptide hormones.

Lanreotide mimics natural somatostatin and binds to somatostatin receptor subtypes 2 and 5. This binding blocks adenylate cyclase, lowers cyclic AMP and calcium influx, and consequently suppresses the release of growth hormone, insulin, glucagon, and various gastrointestinal peptides.

The dosage of Lanreotid Sun is individualized by the prescribing clinician based on the patient’s specific condition, disease severity, and response to therapy. Only a qualified healthcare professional should determine the appropriate dosing regimen.

Safety data for lanreotide in pregnancy and lactation are limited. The product should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To request Lanreotid Sun, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where applicable) and any necessary import documentation.

Lanreotid Sun is a long‑acting somatostatin analogue similar to octreotide but typically requires less frequent subcutaneous administration due to its extended half‑life. Both agents suppress hormone secretion, yet individual patient response, dosing convenience, and specific regulatory approvals may influence the choice of therapy.

Lanreotid Sun should be stored at 2‑8 °C (refrigerated), protected from light, and must not be frozen or shaken. Keep the product in its original packaging to maintain stability and potency.

Lanreotid Sun is given as a sterile solution injected subcutaneously, usually by a healthcare professional. The injection site is typically the abdomen or thigh, and the exact technique follows the prescribing information provided by the clinician.

Serious adverse events reported with lanreotide include pancreatitis, severe allergic reactions such as anaphylaxis, and rare cardiac arrhythmias. Patients should be monitored for signs of abdominal pain, hypersensitivity, or irregular heartbeats and seek immediate medical attention if these occur.

Lanreotid Sun is contraindicated in individuals with known hypersensitivity to lanreotide or any of its excipients. Caution is also advised for patients with severe hepatic or renal impairment, uncontrolled diabetes, or a history of gallbladder disease, and the decision to treat should be made by a qualified clinician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lanreotide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT